The Cooper Companies operates a global contact lens franchise paired with a smaller but fast-growing women's health and fertility business. The strategic question through the back half of fiscal 2026 is whether the market separates a one-time legal charge from an underlying franchise that quietly delivered record revenue and 8% reported growth in the second quarter. The portfolio sits at the intersection of two consumer-anchored healthcare end markets where brand, channel access, and recurring supply economics each carry meaningful weight. The investment narrative hinges on framing the litigation accrual as a non-cash timing event rather than a deterioration in commercial fundamentals, while monitoring settlement progress and accrual revisions through the next two reporting periods.
Net sales reached $1,081.5M in the second fiscal quarter, up 8% on a reported basis. Non-GAAP diluted EPS rose 26% year over year to $1.21, demonstrating that the operating engine inside CooperVision is intact. A litigation accrual drove GAAP EPS to a loss for the quarter. The charge sits inside operating expenses rather than the cash flow statement, where operating cash flow of $443.7M for the half tracked comfortably above the prior year on the strength of the underlying businesses. The second quarter cash generation confirms that the litigation charge is a non-cash timing item rather than a deterioration in commercial fundamentals. The cash flow strength reinforces the value of separating the headline optics from the underlying economic engine when sizing the equity story for the back half of the year.
A $271.6M net pre-tax charge tied to a December 2023 voluntary recall of embryo culture media at CooperSurgical pushed GAAP SG&A sharply higher. The charge erased operating income on a GAAP basis, while non-GAAP operating margin reached 27%, up meaningfully from a year ago. Forward guidance updated to absorb the litigation hit kept total revenue at $4.285B to $4.321B. Within that envelope, CooperVision is guided at $2.883B to $2.908B. CooperSurgical is set on a separate track toward $1.4B. The question is whether the litigation overhang clears with announced settlements, and whether CooperVision can keep converting silicone hydrogel share gains into high-single-digit constant currency growth. Management commentary during the quarter indicated that the litigation settlement path is progressing, with additional case filings and settlement activity shaping the trajectory of the accrual through the balance of the fiscal year.